MHRA-100409-PIP01-21

Key Facts

Active Substance
Active Substance:
  • autologous dendritic cells pulsed with autologous tumour cell lysate
Invented Name
Not yet available
PIP Number MHRA-100409-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Cell suspension for injection
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of high grade glioma
Route(s) of administration
Route(s) of administration:
  • Intradermal use
PIP applicant
  • Northwest Biotherapeutics Inc.
  • Country United States
  • Tel +12404979022
  • Email marnix@nwbio.com
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):autologous dendritic cells pulsed with autologous tumour cell lysate.pdf
Published Date 27/09/2022